"Arcus Biosciences Announces $250 Million Public Offering of Common Stock"

Latham & Watkins LLP participated in the transaction, representing Arcus Biosciences, Inc. in its public offering. Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, announced the pricing of an underwritten public offering of 13,700,000 shares of its common stock at a price of US$18.25 per share, with expected gross proceeds of US$250 million before deducting underwriting discounts, commissions, and offering expenses. The company has also granted the underwriters a 30-day option to purchase up to 2,055,000 additional shares at the public offering price. The offering is expected to close on November 3, 2025, subject to customary closing conditions. The Latham & Watkins LLP team advising Arcus Biosciences was led by Bay Area partners Mark Roeder and John Williams, with associates Caitlin Nguyen and Eddie Magana, and assistance from Connor McCroskey. Intellectual property advice was provided by San Diego/Bay Area partner Christopher Hazuka and San Diego counsel Robert Yeh, with associate Kristina Funahashi. Regulatory matters were handled by Washington, D.C. partner Elizabeth Richards, Bay Area partner Betty Pang, and Washington, D.C. counsel Chad Jennings, with associate Evan Miller. Tax matters were addressed by Bay Area partner Grace Lee, with associate Dennis Poehland. Compensation and benefits matters were managed by Bay Area partner Jay Metz.

"Arcus Biosciences Announces $250 Million Public Offering of Common Stock"

Read the full story

Cookie Preferences

Strictly Necessary

Analytics & Statistics

Marketing & Ads